ArticleCancer communications (London, England)2025
Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades.
Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dietary inflammatory index and risk of major digestive tract cancers: a GRADE-assessed systematic review and dose-response meta-analysis.BMC cancer · 2026Pooled it
- Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.International journal of cancer · 2026Trial
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Alkaloids Mediate Multi-Level Modulation of Gastric Carcinogenesis: From Antibacterial and Anti-Inflammatory Actions to Antitumor Effects.International journal of molecular sciences · 2026Review
- Targeting the Notch signaling pathway in digestive system cancers: from bench to bedside.Cancer cell international · 2026Review
- Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.Nature communications · 2026Article
- Outcomes That Matter in Gastrointestinal Cancer Care: A Focus Group Study of Patient-Centred Outcomes Identified by Patients and Care Partners.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Development and validation of a multivariable CT-based Delta-radiomics model for predicting efficacy to bevacizumab therapy in patients with colorectal liver metastases.Translational cancer research · 2026Article
- Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study.BMC gastroenterology · 2026Article
- Therapeutic Potential of Polysaccharide-Modulated Gut Microbiota-Immune Axis in Gastrointestinal Cancers: Modern Insights From Traditional Pharmacy.Molecular nutrition & food research · 2026Review
- Targeting the crosstalk between Alzheimer's disease and gastrointestinal cancers.Molecular medicine (Cambridge, Mass.) · 2026Review
- Global patterns of upper gastrointestinal cancer incidence by subtype and subsite in 2022: a population-based study.Journal of the National Cancer Center · 2026Article
- Natural Monoterpene Stylosin Induced Anticancer Effects on Human Colon Carcinoma Cells.Pharmacology research & perspectives · 2026Article
- Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms.Cancer cell international · 2026Review
- Trends in gastrointestinal cancers at a major tertiary hospital in Alexandria, Egypt: a 10-year retrospective study (2010-2019).BMC gastroenterology · 2026Article
- Gastrointestinal malignancy in iron deficiency without anemia: a retrospective study from Jordan.Scientific reports · 2026Article
- Artificial Intelligence in Gastrointestinal Wireless Capsule Endoscopy: A Systematic Literature Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2026Review
- Marine Polysaccharides Modulating the Gut Microbiota-Immune Axis in Digestive Tract Tumors: An Update.Marine drugs · 2026Review
- A mechanistic study revealing that SLCO1B3 promotes gastric cancer development and metastasis through MAP1S expression downregulation.BMC cancer · 2026Article
- Hospital-based patterns of esophageal and gastric cancer cases at a major tertiary referral center in Kabul, Afghanistan: a retrospective case series.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe epidemiological profiles of gastrointestinal (GI) cancers vary across countries and over time, largely reflecting variations in risk factors and screening practices. We aimed to provide an overview of the current global burden of the five major types of GI cancers and conduct an updated evaluation of the long-term trends of GI cancers.
methodsThe updated numbers of new cases and deaths, and age-standardized rates (ASR), of the five GI cancers for 185 countries were sourced from the GLOBOCAN 2022, and presented by cancer site, continent, and human development index (HDI). For 43 countries, annual incidence and mortality data were obtained from the Cancer Incidence in Five Continents Plus and World Health Organization mortality databases, supplemented by the mortality data from the Disease Surveillance Points system for China. We compared the long-term trends of ASRs across countries since 1980, and estimated average annual percent changes (AAPCs) for the recent period 2003-2017.
resultsIn 2022, there were 4,783,391 new cases and 3,235,719 deaths from the five GI cancers, accounting for 23.9% and 33.2% of all new cancer cases and deaths worldwide, respectively. Cancers of oesophagus, stomach, and liver were more common in Asian and high HDI countries, and colorectal and pancreatic cancer in western and very high HDI countries. Downward trends were observed in almost all countries for gastric cancer and most countries for oesophageal cancer. For colorectal cancer, the most favorable and unfavorable trends were found in 10 and 19 countries respectively. The largest decreases in liver cancer burden were mainly in eastern and southeastern Asia, while increases were seen in North America, Oceania, and Northern Europe, with AAPCs of 3%∼7% for incidence and 2%∼9% for mortality during 2003-2017. Half of the included countries showed increases in pancreatic cancer burden, with the largest AAPCs in Cyprus, Thailand, India,Türkiye, France, and Belarus for incidence, and Türkiye, Thailand, and China for mortality.
conclusionsDeviating patterns were found for GI cancers worldwide. Multi-setting studies might provide insights into the underlying etiologies of these cancers, and identify areas where urgent cancer control strategies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.